Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Episode | Date |
---|---|
Late April Updates
|
Apr 25, 2024 |
NSCLC In A Nutshell
|
Apr 19, 2024 |
HOPA '24, Site Agnositc T-DXd, & ALINA
|
Apr 11, 2024 |
Tumor Lysis Syndrome
|
Apr 04, 2024 |
Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT
|
Mar 28, 2024 |
Colon Cancer Screening Wars
|
Mar 14, 2024 |
Bladder Cancer Updates
|
Mar 07, 2024 |
SPARED & D-TORCH
|
Feb 29, 2024 |
Lifileucel & FLAURA2 Updates
|
Feb 22, 2024 |
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
|
Feb 15, 2024 |
Small Cell Carcinoma, Prostate Edition
|
Feb 08, 2024 |
Rethinking Some Fundamental Considerations
|
Feb 01, 2024 |
Jan 2024 Updates...
|
Jan 25, 2024 |
Development Of Generic Lenalidomide with Dr. Ryan Beechinor
|
Jan 10, 2024 |
Lenalidomide
|
Jan 04, 2024 |
2023 New Drug Review
|
Dec 21, 2023 |
ASH23 Appetizers
|
Dec 14, 2023 |
VISTA
|
Dec 07, 2023 |
Gamma Secretase Inhibition et al
|
Nov 30, 2023 |
Repotrectinib & Capivasertib
|
Nov 23, 2023 |
Fruquintinib And Osimertinib-Chemo in Combo?
|
Nov 16, 2023 |
Elderly AML & Burkitt Lymphoma Updates
|
Nov 09, 2023 |
Landmarks Of Stage III NSCLC
|
Nov 02, 2023 |
ESMO 2023
|
Oct 26, 2023 |
Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates
|
Oct 19, 2023 |
BRAF V600E Updates
|
Oct 12, 2023 |
Press Release Updates
|
Oct 05, 2023 |
Imatinib [Re-release]
|
Sep 28, 2023 |
Carboplatin Paclitaxel in Ovarian Cancer
|
Sep 21, 2023 |
HER3-DXd & Motixafortide
|
Sep 14, 2023 |
RECISTance Is Futile
|
Sep 07, 2023 |
DPYD Variant Dosing & ICIs In Pancreatic Cancer
|
Aug 31, 2023 |
Nab-Paclitaxel
|
Aug 24, 2023 |
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
|
Aug 17, 2023 |
Talquetamab & STOP-CA
|
Aug 10, 2023 |
Ruby Trial & Quizartinib Toxicity
|
Aug 03, 2023 |
BCOP Study Tips
|
Jul 27, 2023 |
Chemotherapy Sequencing In Colorectal Cancer
|
Jul 20, 2023 |
Phase 1 Clinical Trials In Oncology with Dr. Donald Harvey
|
Jul 13, 2023 |
Investigational Drug Services In Oncology with Dr. Jackie Saunders
|
Jul 06, 2023 |
NADIM II & Favorable Risk RCC
|
Jun 29, 2023 |
Glofitamab & TALAPRO - 2
|
Jun 22, 2023 |
ASCO '23 Entrees
|
Jun 15, 2023 |
ASCO '23 Appetizers
|
Jun 08, 2023 |
PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
|
Jun 01, 2023 |
Epcoritamab
|
May 25, 2023 |
Trimodality Treatment For Bladder Cancer
|
May 18, 2023 |
GAIA-CLL13 & COSMIC-313
|
May 11, 2023 |
SUNLIGHT
|
May 04, 2023 |
QuANTUM First (Quizartinib 1st Line in AML)
|
Apr 27, 2023 |
ICI + Bacterial Supplementation
|
Apr 20, 2023 |
Neoadjuvant Chemo In Breast Cancer
|
Apr 13, 2023 |
Olanzapine & Pembrolizumab (endometrial, urothelial) Updates
|
Apr 06, 2023 |
[Re-release] Tales of Brave Iressa (2017)
|
Mar 30, 2023 |
Linezolid vs. Vanc In Neutropenic Fever
|
Mar 23, 2023 |
Chemo-Induced Ovarian Dysfunction
|
Mar 16, 2023 |
S1801 (Neoadjuvant Pembro In Melanoma)
|
Mar 09, 2023 |
DA-EPOCH (R)
|
Mar 02, 2023 |
Cannabis Use With ICIs
|
Feb 24, 2023 |
Instant KarMMa
|
Feb 16, 2023 |
CodeBreak200 And Elderly AML Survival
|
Feb 09, 2023 |
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
|
Feb 02, 2023 |
HER2 Targeting Era Of Colorectal Cancer Begins
|
Jan 26, 2023 |
Adjuvant Interferon In Melanoma
|
Jan 19, 2023 |
Breast Cancer In A Nutshell
|
Jan 12, 2023 |
Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC
|
Jan 05, 2023 |
2022 New Drug Review
|
Dec 29, 2022 |
Project Renewal: Capecitabine
|
Dec 22, 2022 |
ASH 2022 Highlights
|
Dec 16, 2022 |
TILs, Olutasidenib, T-DXd
|
Dec 08, 2022 |
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
|
Dec 01, 2022 |
Mirvetuximab Soravtansine
|
Nov 17, 2022 |
Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?
|
Nov 10, 2022 |
No Room for MABs at the INN
|
Nov 03, 2022 |
Tremelimumab & Teclistamab
|
Oct 27, 2022 |
Pemetrexed Maintenance
|
Oct 20, 2022 |
Allo CAR-T & Aprepitant For EGFR TKI Pruritis
|
Oct 13, 2022 |
Futibatinib, ESR1, & GPRC5D
|
Oct 06, 2022 |
Thiosulfate And Selpercatinib
|
Sep 29, 2022 |
9 22
|
Sep 22, 2022 |
ESMO 2022 - NICHE-2 and Codebreak 200
|
Sep 15, 2022 |
Biliary Tract Cancer & Pemigatinib (unrelated) Updates
|
Sep 09, 2022 |
Temozolomide + RT For GBM
|
Sep 01, 2022 |
All About Asparaginase
|
Aug 25, 2022 |
HER2 Mutated NSCLC
|
Aug 18, 2022 |
Updated Adjuvant Atezolizumab Data (& more)
|
Aug 11, 2022 |
The Infamous Erlotinib Study
|
Aug 04, 2022 |
Long Term Follow-Up
|
Jul 28, 2022 |
Living With Lupus
|
Jul 14, 2022 |
ICIs & PPIs - Something to Worry About?
|
Jul 07, 2022 |
APAP + ICI: An emerging concern?
|
Jun 30, 2022 |
FN Updates
|
Jun 23, 2022 |
LGBTQ Clinical Pearls
|
Jun 16, 2022 |
ASCO 2022 Highlights
|
Jun 09, 2022 |
Transgender Cancer Screening
|
Jun 02, 2022 |
What's Next In NSCLC & AML?
|
May 26, 2022 |
How To Use Our Favorite Guidelines
|
May 19, 2022 |
Docetaxel
|
May 12, 2022 |
Adjuvant HD Cisplatin-RT For High Risk Head & Neck Cancer
|
May 05, 2022 |
Melanoma In A Nutshell
|
Apr 28, 2022 |
Loong TFRs In CML, A Lack Of Agility, & CHEKCMATE 816
|
Apr 21, 2022 |
Ribociclib-Tamoxifen: A Cautionary Tale
|
Apr 14, 2022 |
Relatlimab + Nivo And the VISION trial
|
Apr 07, 2022 |
HOPA Boston Preview
|
Mar 28, 2022 |
DESTINY-Breast03
|
Mar 24, 2022 |
Chemo Toxicity Prediction & Risk
|
Mar 17, 2022 |
Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)
|
Mar 10, 2022 |
7 + 3
|
Mar 03, 2022 |
Prostate Ca Updates From ASCO GU 22
|
Feb 24, 2022 |
Bacillus Calmette-Guerin
|
Feb 17, 2022 |
KIR, HLA - C, & Rituximab
|
Feb 10, 2022 |
GI Cancer Updates & Tebentafusp
|
Feb 03, 2022 |
Precision Medicine Demystified
|
Jan 27, 2022 |
New Hallmarks Of Cancers & LenPembro For Endometrial Cancer
|
Jan 20, 2022 |
Carfilzomib
|
Jan 13, 2022 |
So, You Want to Work (from home) as a Specialty Pharmacist
|
Jan 06, 2022 |
Drugs of 2021: Keep, Return Or Re-gift?
|
Dec 23, 2021 |
ASH21 The More Things Change...
|
Dec 16, 2021 |
So, You Want to be a Pediatric Oncology Pharmacist
|
Dec 09, 2021 |
Dasatinib Dosing & DREAMseq
|
Dec 02, 2021 |
Sun's Out, T Cells Out
|
Nov 18, 2021 |
So, You Want To Be An MSL Oncology Pharmacist
|
Nov 11, 2021 |
Asciminib
|
Nov 04, 2021 |
Adjuvant Atezo, Palbo-PPI Interaction? And More
|
Oct 28, 2021 |
Decreased Cardiotoxicity With Infusional Doxorubicin
|
Oct 21, 2021 |
Adjuvant Abemaciclib
|
Oct 14, 2021 |
Same Day Pegfilgrastim
|
Oct 07, 2021 |
Sarcomas In A Nutshell
|
Sep 30, 2021 |
ESMO21 & New Drugs (Cervical Ca Focus)
|
Sep 23, 2021 |
CASSIOPEIA Part 2
|
Sep 16, 2021 |
MMF For ITP
|
Sep 09, 2021 |
Hypercalcemia Of Malignancy (in Under 10)
|
Sep 02, 2021 |
Belzutifan and Recent Updates
|
Aug 26, 2021 |
Booster COVID-19 Vaccinations in Immunocompromised Patients
|
Aug 19, 2021 |
Sneaky TKI Toxicities
|
Aug 12, 2021 |
Acala V. Ibrutinib(again) & VidazaAllo
|
Aug 05, 2021 |
Breast Cancer & cGVHD Updates
|
Jul 29, 2021 |
GOG-172 (IP chemotherapy in ovarian cancer)
|
Jul 22, 2021 |
Advertising Amateur Hour
|
Jul 15, 2021 |
Capecitabine
|
Jul 08, 2021 |
Hormonal Toxicity Management In Breast Cancer Pts
|
Jul 01, 2021 |
EA1131 & TOURMALINE
|
Jun 24, 2021 |
Why Learning Oncology Is Hard
|
Jun 18, 2021 |
ASCO 2021
|
Jun 10, 2021 |
Sotorasib, Infigratinib, And More
|
Jun 03, 2021 |
Amivantamab
|
May 27, 2021 |
Venetoclax (with Dr. Kayleigh Marx)
|
May 20, 2021 |
Dosing In Obesity
|
May 13, 2021 |
Dostarlimab, Loncastuximab tesirine, & HER2 GI Updates
|
May 06, 2021 |
A Landmark Trial (without an FDA approval)
|
Apr 29, 2021 |
COVID Vaccine (Myeloma & CLL), MANHATTAN And More
|
Apr 22, 2021 |
IO Uh Oh
|
Apr 15, 2021 |
Cancer COVID Vaccine Updates + AMBORO
|
Apr 08, 2021 |
ICIs In Esophageal & GEJ Cancers
|
Apr 01, 2021 |
Emend's Emergence
|
Mar 25, 2021 |
Tivozanib (and More)
|
Mar 18, 2021 |
Indolent Lymphoma Week
|
Mar 12, 2021 |
Melphalan Flufenamide
|
Mar 04, 2021 |
Trilaciclib, Cemiplimab & GU Updates
|
Feb 25, 2021 |
Filgrastim Turns 30
|
Feb 18, 2021 |
Umbralisib
|
Feb 11, 2021 |
Tepotinib
|
Feb 04, 2021 |
Updates on mRCC and COVID-19 Vaccination
|
Jan 28, 2021 |
Updates T-DXd (gastric) & SC Dara (AL Amyloidosis)
|
Jan 21, 2021 |
JBR10
|
Jan 14, 2021 |
Updates from December 2020
|
Jan 07, 2021 |
Trastuzumab
|
Dec 31, 2020 |
Best Of 2020
|
Dec 23, 2020 |
COVID Vaccines In Cancer Patients - What We Don't Know
|
Dec 17, 2020 |
Breast Cancer Updates Dec. 2020
|
Dec 11, 2020 |
Colon Cancer Updates (IDEA & Keynote - 177)
|
Dec 03, 2020 |
CLOT
|
Nov 24, 2020 |
Pembrolizumab for TNBC & CML Updates
|
Nov 19, 2020 |
Ifosfamide
|
Nov 12, 2020 |
BELLINI
|
Nov 05, 2020 |
Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT Maintenance
|
Oct 29, 2020 |
Monthly Immunotherapy Expanded Approvals Update
|
Oct 21, 2020 |
Fulvestrant's Fumbled Dosing
|
Oct 15, 2020 |
Dexamethasone
|
Oct 08, 2020 |
IMpower 110 & Checkmate 153
|
Oct 01, 2020 |
ESMO 2020 & Beyond
|
Sep 24, 2020 |
TAX 327
|
Sep 17, 2020 |
Pralsetinib
|
Sep 11, 2020 |
BROCADE3
|
Sep 03, 2020 |
Alopecia
|
Aug 27, 2020 |
ATAC
|
Aug 20, 2020 |
VIALE-A (venetoclax + azacitidine for elderly/unfit AML)
|
Aug 13, 2020 |
New Anti-CD-19 And BCMA Options
|
Aug 06, 2020 |
Gemcitabine
|
Jul 30, 2020 |
Antiemetic & CIPN Guideline Updates
|
Jul 23, 2020 |
Conversation With A Breast Cancer Survivor
|
Jul 16, 2020 |
Neutropenic Fever 101
|
Jul 09, 2020 |
Early July FDA Updates
|
Jul 02, 2020 |
Clinical Trial Endpoints in Oncology
|
Jun 25, 2020 |
Lurbinectedin et al
|
Jun 18, 2020 |
LD Vs Ld
|
Jun 11, 2020 |
ASCO 2020
|
Jun 04, 2020 |
More NSCLC Updates (Checkmate-9La & ALTA-1L)
|
May 28, 2020 |
New Chemo - Free Immunotherapy Options For NSCLC
|
May 21, 2020 |
Selpercatinib & More!
|
May 14, 2020 |
Capmatinib & SC Daratumumab
|
May 08, 2020 |
Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin
|
Apr 30, 2020 |
Sacituzumab Govitecan, Tucatinib, And More!
|
Apr 24, 2020 |
Journal Club: Unscheduled Hydration in Patients Receiving HEC
|
Apr 16, 2020 |
Bevacizumab's Wild Ride For Metastatic Breast Cancer
|
Apr 09, 2020 |
Caravaggio
|
Apr 02, 2020 |
Bleomycin
|
Mar 27, 2020 |
Recent Landmarks (CLEOPATRA, Keynote189)
|
Mar 19, 2020 |
*Covid19 And Chemo*
|
Mar 16, 2020 |
Viz-Aflibercept Pricing: A Case Study
|
Mar 12, 2020 |
Pre - HOPA News Dunp
|
Mar 05, 2020 |
CYP2D6 & Tamoxifen Updates
|
Feb 27, 2020 |
CAR - NK
|
Feb 13, 2020 |
NK - 1 Antagonist Drug Interactions
|
Feb 06, 2020 |
Tazemetostat
|
Jan 30, 2020 |
Bendamustine
|
Jan 23, 2020 |
Avapritinib
|
Jan 16, 2020 |
Safety Signals & 6 - MP Hepatotoxicity
|
Jan 09, 2020 |
Trastuzumab Deruxtecan
|
Jan 02, 2020 |
Enfortumab-vedotin (& Asciminib)
|
Dec 26, 2019 |
Arsenic Sauce
|
Dec 19, 2019 |
ASH '19 Updates
|
Dec 12, 2019 |
Dose Dense AC
|
Dec 05, 2019 |
Cornucopia Of OncoPharm Updates
|
Nov 27, 2019 |
Zanubrutinib
|
Nov 21, 2019 |
Immunotherapy Interactions
|
Nov 14, 2019 |
Data Dive Into NK-1 Antagonists & Carboplatin
|
Nov 07, 2019 |
Carboplatin
|
Oct 31, 2019 |
ADAM VTE & Ibrutinib CV Toxicity
|
Oct 24, 2019 |
To Rechallenge, Or Not To Rechallenge
|
Oct 17, 2019 |
CASPIAN
|
Oct 10, 2019 |
ESMO 2019
|
Oct 03, 2019 |
Danorubicin 90 mg/m2 (AML induction)
|
Sep 24, 2019 |
New FDA approved indications for lenvatinib, pembro, and apalutamide
|
Sep 19, 2019 |
Curious Case Of Ibrutinib On Netflix
|
Sep 12, 2019 |
OncoPharm M & M Extreme Toxicity & Pharmacogenetics
|
Sep 05, 2019 |
Irinotecan
|
Aug 29, 2019 |
Entrectinib & Fedratinib
|
Aug 22, 2019 |
E1912: Ibrutinib/rituximab vs. FCR in CLL
|
Aug 15, 2019 |
ASCO VTE Guidelines (& more!)
|
Aug 08, 2019 |
Darolutamide
|
Jul 31, 2019 |
AC - - > T (q week)
|
Jul 25, 2019 |
Selinexor
|
Jul 18, 2019 |
Pain Management In Cancer
|
Jul 11, 2019 |
Tamoxifen
|
Jul 03, 2019 |
Ask OncoPharm: Advice for PGY2 Oncology Pharmacy Residents
|
Jun 27, 2019 |
Pembrolizumab Nets 2 More Approvals
|
Jun 20, 2019 |
Polatuzumab-vedotin
|
Jun 13, 2019 |
ASCO '19
|
Jun 06, 2019 |
Alpelisib
|
May 30, 2019 |
AC - - > T (q 3 week)
|
May 23, 2019 |
AC (NSABP B-15)
|
May 23, 2019 |
May Approvals, More Questions
|
May 16, 2019 |
Imatinib
|
May 09, 2019 |
Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML
|
May 02, 2019 |
Lenvatinib vs. Sorafenib (HCC)
|
Apr 24, 2019 |
Erdafitinib
|
Apr 18, 2019 |
HOPA '19 Reflections
|
Apr 11, 2019 |
OncoPharm M & M - Drug Interaction
|
Apr 02, 2019 |
Etoposide
|
Mar 28, 2019 |
Updates: Venetoclax use in multiple myeloma, atezolizumab in small cell lung cancer
|
Mar 21, 2019 |
Metastatic Pancreatic CAncer
|
Mar 14, 2019 |
S.C. Monoclonal Antibodies
|
Mar 08, 2019 |
Lessons Learned (from the last week)
|
Feb 28, 2019 |
Axitinib's Big Weekend
|
Feb 21, 2019 |
IRIS
|
Feb 14, 2019 |
Cannabidiol (CBD) & Potential Drug Interactions In Cancer Patients
|
Feb 07, 2019 |
Mucositis & Stomatitis
|
Jan 31, 2019 |
Olaratumab, Goodbye?
|
Jan 24, 2019 |
Conversation With An Osteosarcoma Survivor
|
Jan 17, 2019 |
New & Niche Drugs
|
Jan 10, 2019 |
mFOLFIRINOX
|
Jan 03, 2019 |
Let's Talk About Mr. Gower
|
Dec 20, 2018 |
FOLFOX (MOSAIC Trial)
|
Dec 13, 2018 |
Gilteritinib
|
Dec 05, 2018 |
Elderly AML & Larotrectinib
|
Nov 27, 2018 |
Rise (& Fall) Of ESAs
|
Nov 21, 2018 |
Cyclophosphamide
|
Nov 15, 2018 |
Lorlatinib
|
Nov 06, 2018 |
October '18 Updates
|
Nov 01, 2018 |
Flu Vaccine Use with Immunotherapy
|
Oct 25, 2018 |
Talazoparib
|
Oct 18, 2018 |
P1: Tamoxifen for Breast Cancer Risk Reduction
|
Oct 11, 2018 |
Dacomitinib, cemiplimab & #oncopharm updates
|
Oct 04, 2018 |
Duvelisib
|
Sep 26, 2018 |
The Pseudomonas Exotoxin Drug
|
Sep 20, 2018 |
*Bonus Pod* World Marrow Donor Day '18
|
Sep 15, 2018 |
5-Fluorouracil
|
Sep 14, 2018 |
Ask OncoPharm (Part 1) & RELEVANCE
|
Sep 06, 2018 |
Influenza Vaccination during Chemo
|
Aug 30, 2018 |
Small Cell Lung Cancer: Established & Recent Advances
|
Aug 23, 2018 |
Mogamulizumab & August updates
|
Aug 16, 2018 |
Rituximab
|
Aug 09, 2018 |
Iobenguane I-131 & Lusutrombopag
|
Aug 02, 2018 |
Ivosidenib
|
Jul 26, 2018 |
A Brief History of Pemetrexed
|
Jul 20, 2018 |
Paclitaxel
|
Jul 11, 2018 |
Happy Fourth!
|
Jul 04, 2018 |
Encorafenib & Binimetinib
|
Jun 28, 2018 |
The Immunotherapy Two Step
|
Jun 21, 2018 |
Ondansetron Origins
|
Jun 13, 2018 |
Less is More & More
|
Jun 07, 2018 |
ASCO18 & Under the Radar Abstracts
|
May 31, 2018 |
Avatrombopag
|
May 25, 2018 |
PERSEPHONE: Bonus Pod
|
May 19, 2018 |
Cytarabine
|
May 18, 2018 |
Dual TKI Use & Frontline Dara
|
May 10, 2018 |
Methotrexate
|
May 04, 2018 |
AACR Update
|
Apr 19, 2018 |
NSABP-14
|
Apr 13, 2018 |
Vincristine
|
Apr 06, 2018 |
HOPA Highlights and Catching Up with NEJOncology
|
Mar 30, 2018 |
HOPA Preview
|
Mar 16, 2018 |
Landmark Testicular Cancer Study PVB (& BEP & EP)
|
Mar 09, 2018 |
Cycling thru the CDK Inhibitors
|
Mar 01, 2018 |
It's All Immunotherapy Nowadays
|
Feb 23, 2018 |
Apalutamide
|
Feb 15, 2018 |
Landmarks in Oncology Pharmacy: CMF
|
Feb 09, 2018 |
Foundations in Oncology Pharmacy: Doxorubicin
|
Feb 02, 2018 |
Updates in Oncology Pharmacy: Lu-177
|
Jan 26, 2018 |
Landmarks in Oncology Pharmacy: MOPP
|
Jan 19, 2018 |
Foundations in Oncology Pharmacy: Cisplatin
|
Jan 12, 2018 |
Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
|
Jan 05, 2018 |
Landmarks in Oncology Pharmacy: Acute Leukemia in 1958
|
Jan 01, 2018 |
2017 Was A Good Year
|
Dec 18, 2017 |
Tales of Brave Iressa
|
Nov 30, 2017 |
Adjuvant TKIs?
|
Nov 17, 2017 |
Acalabrutinib
|
Nov 01, 2017 |